These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36409923)
1. Phenotypic variation in severe hemophilia A is related to endogenous thrombin potential and plasma levels of factor VII. Chaves DG; Fonseca FML; Araújo HCB; de Oliveira LMM; Amorim MVA; Assis Neto CC; Carvalho MDG Blood Coagul Fibrinolysis; 2022 Dec; 33(8):463-467. PubMed ID: 36409923 [TBL] [Abstract][Full Text] [Related]
2. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. Santagostino E; Mancuso ME; Tripodi A; Chantarangkul V; Clerici M; Garagiola I; Mannucci PM J Thromb Haemost; 2010 Apr; 8(4):737-43. PubMed ID: 20102490 [TBL] [Abstract][Full Text] [Related]
3. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors. Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575 [TBL] [Abstract][Full Text] [Related]
4. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A. Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420 [TBL] [Abstract][Full Text] [Related]
5. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype. Milos M; Coen Herak D; Mahmoud Hourani Soutari N; Pavic J; Zupancic-Salek S; Zadro R; Antovic JP Int J Lab Hematol; 2021 Apr; 43(2):273-280. PubMed ID: 32964648 [TBL] [Abstract][Full Text] [Related]
6. Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency. Tran HT; Tjønnfjord GE; Holme PA Haemophilia; 2014 Jan; 20(1):141-6. PubMed ID: 23992369 [TBL] [Abstract][Full Text] [Related]
7. Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease. Verhagen MJA; van Balen EC; Blijlevens NMA; Coppens M; van Heerde WL; Leebeek FWG; Rijpma SR; van Vulpen LFD; Gouw SC; Schols SEM J Thromb Haemost; 2024 Jan; 22(1):152-162. PubMed ID: 37813197 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of recombinant activated factor VII: an update. Hedner U Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375 [TBL] [Abstract][Full Text] [Related]
9. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. van't Veer C; Mann KG Semin Thromb Hemost; 2000; 26(4):367-72. PubMed ID: 11092210 [TBL] [Abstract][Full Text] [Related]
10. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Al Dieri R; Peyvandi F; Santagostino E; Giansily M; Mannucci PM; Schved JF; Béguin S; Hemker HC Thromb Haemost; 2002 Oct; 88(4):576-82. PubMed ID: 12362226 [TBL] [Abstract][Full Text] [Related]
11. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). van 't Veer C; Golden NJ; Kalafatis M; Simioni P; Bertina RM; Mann KG Blood; 1997 Oct; 90(8):3067-72. PubMed ID: 9376587 [TBL] [Abstract][Full Text] [Related]
12. Potential role of recombinant factor VIIa as a hemostatic agent. Hedner U; Erhardtsen E Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390 [TBL] [Abstract][Full Text] [Related]
13. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Tarandovskiy ID; Balandina AN; Kopylov KG; Konyashina NI; Kumskova MA; Panteleev MA; Ataullakhanov FI Thromb Res; 2013 Jun; 131(6):e274-80. PubMed ID: 23611257 [TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B. Tardy-Poncet B; Montmartin A; Chambost H; Lienhart A; Frotscher B; Morange PE; Falaise C; Collange F; Dargaud Y; Toussaint-Hacquard M; Ardillon L; Wibaut B; Jeanpierre E; Nguyen P; Volot F; Tardy B Haemophilia; 2024 May; 30(3):693-701. PubMed ID: 38650319 [TBL] [Abstract][Full Text] [Related]
15. In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype. Verhagen MJA; van Heerde WL; van der Bom JG; Beckers EAM; Blijlevens NMA; Coppens M; Gouw SC; Jansen JH; Leebeek FWG; van Vulpen LFD; Meijer D; Schols SEM Res Pract Thromb Haemost; 2023 Feb; 7(2):100062. PubMed ID: 36865907 [TBL] [Abstract][Full Text] [Related]
16. Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation. Castoldi E; Govers-Riemslag JW; Pinotti M; Bindini D; Tans G; Berrettini M; Mazzucconi MG; Bernardi F; Rosing J Blood; 2003 Dec; 102(12):4014-20. PubMed ID: 12881304 [TBL] [Abstract][Full Text] [Related]
18. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Parameswaran R; Shapiro AD; Gill JC; Kessler CM; Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910 [TBL] [Abstract][Full Text] [Related]
19. Thromboelastography in children with coagulation factor deficiencies. Chitlur M; Warrier I; Rajpurkar M; Hollon W; Llanto L; Wiseman C; Lusher JM Br J Haematol; 2008 Jun; 142(2):250-6. PubMed ID: 18492116 [TBL] [Abstract][Full Text] [Related]